JP2024150445A5 - - Google Patents

Download PDF

Info

Publication number
JP2024150445A5
JP2024150445A5 JP2024099523A JP2024099523A JP2024150445A5 JP 2024150445 A5 JP2024150445 A5 JP 2024150445A5 JP 2024099523 A JP2024099523 A JP 2024099523A JP 2024099523 A JP2024099523 A JP 2024099523A JP 2024150445 A5 JP2024150445 A5 JP 2024150445A5
Authority
JP
Japan
Prior art keywords
antigen
binding protein
seq
pharmaceutical composition
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024099523A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024150445A (ja
Filing date
Publication date
Priority claimed from JP2020515692A external-priority patent/JP7599332B2/ja
Application filed filed Critical
Publication of JP2024150445A publication Critical patent/JP2024150445A/ja
Publication of JP2024150445A5 publication Critical patent/JP2024150445A5/ja
Pending legal-status Critical Current

Links

JP2024099523A 2017-09-18 2024-06-20 クローディン6抗体及びがんを治療するための方法 Pending JP2024150445A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762560143P 2017-09-18 2017-09-18
US62/560,143 2017-09-18
JP2020515692A JP7599332B2 (ja) 2017-09-18 2018-09-18 クローディン6抗体及びがんを治療するための方法
PCT/US2018/051610 WO2019056023A2 (en) 2017-09-18 2018-09-18 ANTIBODIES AGAINST CLAUDIN 6 AND METHODS OF TREATING CANCER

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020515692A Division JP7599332B2 (ja) 2017-09-18 2018-09-18 クローディン6抗体及びがんを治療するための方法

Publications (2)

Publication Number Publication Date
JP2024150445A JP2024150445A (ja) 2024-10-23
JP2024150445A5 true JP2024150445A5 (https=) 2026-02-06

Family

ID=65723110

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020515692A Active JP7599332B2 (ja) 2017-09-18 2018-09-18 クローディン6抗体及びがんを治療するための方法
JP2024099523A Pending JP2024150445A (ja) 2017-09-18 2024-06-20 クローディン6抗体及びがんを治療するための方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020515692A Active JP7599332B2 (ja) 2017-09-18 2018-09-18 クローディン6抗体及びがんを治療するための方法

Country Status (22)

Country Link
US (4) US20200291111A1 (https=)
EP (2) EP3826667B1 (https=)
JP (2) JP7599332B2 (https=)
KR (2) KR102793719B1 (https=)
CN (2) CN111565744B (https=)
AU (2) AU2018334434B2 (https=)
BR (1) BR112020005196A2 (https=)
CA (1) CA3076207A1 (https=)
CZ (1) CZ2021138A3 (https=)
DK (1) DK3826667T3 (https=)
ES (1) ES2986343T3 (https=)
FI (1) FI3826667T3 (https=)
GB (1) GB202103867D0 (https=)
HU (1) HUE067603T2 (https=)
IL (2) IL273196B2 (https=)
MX (2) MX2020002921A (https=)
NO (1) NO20210351A1 (https=)
PL (1) PL3826667T3 (https=)
PT (1) PT3826667T (https=)
SG (1) SG11202002114RA (https=)
SI (1) SI3826667T1 (https=)
WO (1) WO2019056023A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO20210351A1 (en) * 2017-09-18 2021-03-18 Univ California Claudin6 antibodies and methods of treating cancer
NZ762505A (en) 2017-09-29 2026-03-27 Daiichi Sankyo Co Ltd Antibody-pyrrolobenzodiazepine derivative conjugate
KR102063341B1 (ko) * 2018-12-31 2020-01-07 다이노나(주) Icam-1에 특이적으로 결합하는 항체 및 그의 용도
MA54955A (fr) 2019-02-15 2021-12-22 Integral Molecular Inc Anticorps anti-claudine 6 et leurs utilisations
US20220177583A1 (en) * 2019-03-20 2022-06-09 The Regents Of The University Of California Claudin-6 bispecific antibodies
DK3941946T3 (da) * 2019-03-20 2025-03-24 Univ California Claudin-6-antistoffer og lægemiddelkonjugater
JP2023529557A (ja) 2020-05-04 2023-07-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗enpp1抗体の阻害
CN112386687B (zh) * 2020-12-09 2021-05-04 爱龄医美国际健康咨询服务(北京)有限公司 一种干细胞外泌体及其在药品和化妆品中的应用
WO2023091512A2 (en) * 2021-11-16 2023-05-25 Allakos, Inc. Antibodies to anti-siglec-9 and multispecific antibodies targeting siglec-7 and siglec-9
EP4475852A4 (en) * 2022-02-09 2026-05-06 Sera Prognostics Inc Shbg and ibp4 antibodies and methods using same
TW202430574A (zh) 2022-11-30 2024-08-01 美商積分分子股份有限公司 針對密連蛋白6之抗體,包括其雙特異性格式
IL324834A (en) 2023-05-25 2026-01-01 Univ California Dosage of claudin-6 conjugates for cancer treatment
WO2025075127A1 (ja) * 2023-10-04 2025-04-10 公立大学法人福島県立医科大学 がんのバイオマーカー及び抗体治療
TW202542202A (zh) * 2024-01-04 2025-11-01 美商翰森生物有限責任公司 抗體、抗原結合片段及其醫療用途
WO2025162270A1 (zh) * 2024-02-01 2025-08-07 江苏恒瑞医药股份有限公司 抗cldn6抗体、其抗体-药物偶联物及其医药用途
WO2026084392A1 (ko) * 2024-10-14 2026-04-23 에이비엘바이오 주식회사 항-클라우딘6 항체 및 이의 용도

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
EP0184365B1 (en) 1984-12-04 1993-08-04 Eli Lilly And Company Improvements in the treatment of tumors in mammals
EP1053752A1 (en) 1998-02-10 2000-11-22 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
AU756796B2 (en) 1998-10-16 2003-01-23 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Combination therapy with VIP antagonist
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
AU2003279842A1 (en) 2002-10-04 2004-05-04 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
CA2672581A1 (en) * 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
WO2008130158A1 (en) 2007-04-19 2008-10-30 Dong-A Pharmaceutical. Co., Ltd A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
EP2241578B1 (en) * 2008-01-11 2016-04-20 The University of Tokyo Anti-cldn6 antibody
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
ES2989943T3 (es) * 2011-05-13 2024-11-28 Astellas Pharma Inc Anticuerpos para el tratamiento de un cáncer que expresa la Claudina 6
WO2015014376A1 (en) * 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
RU2016122041A (ru) * 2013-11-06 2017-12-11 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Новые анти-клаудин антитела и способы их применения
PT3514172T (pt) 2014-04-01 2020-04-21 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Imunorrecetores específicos de claudina-6 e epítopos de células t
NO20210351A1 (en) * 2017-09-18 2021-03-18 Univ California Claudin6 antibodies and methods of treating cancer

Similar Documents

Publication Publication Date Title
JP2024150445A5 (https=)
JP2023051986A (ja) Cd47に対するヒト化及びキメラモノクローナル抗体
JP7784511B2 (ja) 抗ネクチン-4抗体、それを含むコンジュゲート、及びその適用
JP2003525061A5 (https=)
CN107735093A (zh) Cd123抗体和其结合物
WO2023025243A1 (zh) 抗Nectin-4抗体、药物缀合物及其制备方法和用途
JP2024501894A5 (https=)
CN111655290A (zh) 抗组织因子抗体-药物偶联物及其在癌症治疗中的应用
JP2024537323A5 (https=)
JP2023536631A5 (https=)
WO2024163630A2 (en) Anti-cdh17 antibodies and use of the same
JP2023516195A (ja) C19 c38二特異性抗体
US11110179B2 (en) Combination of CD33 antibody drug conjugates with chemotherapeutic agents
US20180296691A1 (en) Anti-efna4 antibody-drug conjugates
JP2025506143A5 (https=)
CN113135995A (zh) 抗her3单克隆抗体及其应用
WO2023065594A1 (zh) 抗cd47-cldn18.2双特异性抗体及其用途
CN112996540B (zh) 一种c-Met ADC在制备治疗c-Met激酶抑制剂耐药的疾病的药物中的用途
JP2022530063A (ja) 抗体製剤
US20250092152A1 (en) Humanized antibody capable of binding to heg1 protein
CN120077073A (zh) 用于治疗里希特氏综合征的针对cd3和cd20的双特异性抗体
CN120695174A (zh) 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用
JP2022535276A5 (https=)
JP2023536630A5 (https=)
TWI922217B (zh) 用於治療類風濕性關節炎的抗體及其用途